S&P 500 7,457.69 -1.01% NASDAQ 25,520.24 -1.40% DOW 52,146.42 -0.77% R2K 2,962.22 -0.42% VIX 18.77 +12.19% US 10Y 4.54 -0.61% DXY 100.75 +0.02% GOLD 4,012.70 +0.68% CRUDE 82.49 +4.48%
Next Bullish Trade
Sign in
CERO

CERO CERO

$0.01 +0.00 (-8.33%)
Neutral · -0.47σ
+ Compare Open in Sniper

Price chart

Timeframe
Range
Fundamentals · free Click ▲ earnings markers (daily) for the day's move

Loading…

Latest bar · CERO

Momentum reads · latest daily bar
Last
$0.01
+-0.00 (-8.33%)
Mkt cap
$0M
Healthcare
RSI(14)
43.6
neutral
Stochastic %K
26.7
neutral
MFI(14)
65.8
neutral
ADX(14)
23.3
building

Green means room to run, red means stretched — the reads re-read live as you switch the chart's timeframe. MFI(14) is a volume-weighted money-flow read: above 80 = overbought, below 20 = oversold.

Financial overlay · last 12 quarters

The story behind the price: three years of quarterly results laid over the chart, so you can see whether the stock has been following the business — or running ahead of it.

QuarterRevenue Net incomeOp income FCFNet margin Op margin
2026-03-31 — $-0.0B $-0.0B $-0.0B — —
2025-12-31 — $-0.0B $-0.0B $-0.0B — —
2025-09-30 — $-0.0B $-0.0B $-0.0B — —
2025-06-30 — $-0.0B $-0.0B $-0.0B — —
2025-03-31 — $-0.0B $-0.0B $-0.0B — —

Tip: toggle P/E, FCF, ROE, Gross margin and more on the chart above — every overlay is free.

Compare CERO vs peers

Line CERO up against up to 4 peers (5 tickers total) across ~30 metrics and get one weighted 0-100 verdict — best in green, worst in red. Peers also overlay on the chart above as rebased % lines, or flip the chart to the 2×2 grid for side-by-side mini charts.

Comparing CERO no peers yet — add up to 4 below
Sector peers + LLY + UNH + JNJ + MRK + ABBV + PFE
Popular + AAPL + MSFT + NVDA + AMZN + GOOG + META + TSLA + AVGO
Matchups NVDA · AMD · AVGO · SMCI · MU AAPL · MSFT · GOOG · META · AMZN JPM · GS · MS · BAC · C TSLA · RIVN · LCID · GM · F XOM · CVX · OXY · COP

Add tickers to compare with CERO

~30 metrics across Snapshot, OdysseyHQ zone, Valuation, Growth, Quality, Technicals, Sentiment, and Risk — with a weighted score and a one-line read on each.

Earnings replay · last 3 reports

How this stock actually behaves on report day: each past earnings print with the beat-or-miss and the next-day move — a track record for handicapping the next one.

DateEPS actual EPS estSurprise Next-day
2025-11-19 -9.10 -4.35 -109.2% +16.7%
2025-08-22 -61.71 -6.21 -893.7% -5.3%
2025-05-15 -31.80 -119.20 +73.3% +0.2%

Earnings markers are overlaid on the daily price chart above. Click a ▲ marker for that day's move.

Peer comparison · Healthcare

Context check: the same key numbers for the closest Healthcare names side by side, so you can tell whether this stock is the standout or just moving with its group.

Ticker ⇅ Mkt cap ⇅ P/E ⇅ Fwd P/E ⇅ P/S ⇅ EV/EBITDA ⇅ P/B ⇅ Gross M ⇅ Rev gr ⇅ EPS gr ⇅ FCF yld ⇅
CERO ★ $0B 0.0 -0.0 — -0.4 -0.0 — — — -743.34%
LLY $1,051B 41.8 26.3 14.6 30.1 33.8 82.8% 55.5% 169.9% 0.87%
UNH $387B 32.1 19.2 0.9 17.7 4.0 19.5% 0.4% 61.5% 5.88%
JNJ $609B 29.3 19.7 6.2 18.4 7.5 68.1% 6.6% -1.0% —
MRK $315B 36.0 13.2 4.8 12.1 6.9 76.7% 4.9% — 4.46%
ABBV $450B 124.8 15.6 7.2 17.2 -67.6 72.0% 12.4% -46.2% 4.63%
PFE $143B 19.1 8.8 2.3 7.6 1.6 74.8% 5.4% -10.1% 8.67%
TMO $198B 29.2 19.5 4.4 21.1 3.8 40.9% 6.2% 11.3% 2.79%

Auto-seeded from sector. Click any ticker to switch.

Ownership

Who holds the stock and what they've been doing lately — big funds on the left, executives' own buys and sells on the right. Insider buying is the rarer, louder signal.

Top institutional holders

Top-10 concentration: 0.12%

HolderShares% out
Arch Venture Management, Llc 22,389 0.08%
Susquehanna International Group, LLP 10,244 0.04%
Jones Financial Companies, L.L.L.P. 3 —
Tower Research Capital LLC (TRC) 1,299 —
Bank of America Corporation 3 —
Royal Bank of Canada 1 —

Insider activity · 90d

No insider trades for CERO in last 90d.

Analyst estimates

Finnhub

What Wall Street expects next: the consensus forecasts for the coming quarters. The market usually reacts to results versus these numbers, not the raw results themselves.

Low
$—
Mean
$—
High
$—
Analysts
—
Recommendation distribution · period 2026-07-01
4
1
2
Revision trend (2026-04-01 → 2026-07-01): net -3 → -3 0 (net = strong_buy+buy − sell−strong_sell)

SEC filings

The company's own paperwork, straight from the regulator — annual and quarterly reports, big announcements and insider trades. The primary source behind every headline.

FormFiled DescriptionAction
8-K 2026-07-17 CURRENT REPORT view ·
8-K 2026-06-26 CURRENT REPORT view ·
8-K 2026-05-29 CURRENT REPORT view ·
10-Q 2026-05-15 QUARTERLY REPORT view ·
8-K 2026-05-01 CURRENT REPORT view ·
4 2026-04-21 Insider transaction (Form 4) view ·
10-K 2026-04-15 ANNUAL REPORT view ·
8-K 2026-04-14 CURRENT REPORT view ·
8-K 2026-03-11 CURRENT REPORT view ·
8-K 2026-02-13 FORM 8-K view ·
8-K 2026-02-04 CURRENT REPORT view ·
8-K 2026-02-03 CURRENT REPORT view ·
4 2026-01-09 Insider transaction (Form 4) view ·
4 2026-01-09 Insider transaction (Form 4) view ·
4 2026-01-09 Insider transaction (Form 4) view ·
4 2026-01-09 Insider transaction (Form 4) view ·
4 2026-01-09 Insider transaction (Form 4) view ·
4 2026-01-09 Insider transaction (Form 4) view ·
4 2026-01-09 Insider transaction (Form 4) view ·
4 2026-01-09 Insider transaction (Form 4) view ·
8-K 2026-01-07 CURRENT REPORT view ·
8-K 2025-12-19 CURRENT REPORT view ·
S-1 2025-12-05 REGISTRATION STATEMENT view ·
8-K 2025-12-02 CURRENT REPORT view ·
DEF 14A 2025-11-28 PROXY STATEMENT view ·
10-Q 2025-11-19 QUARTERLY REPORT view ·
8-K 2025-10-30 CURRENT REPORT view ·
8-K 2025-10-16 CURRENT REPORT view ·
8-K 2025-10-14 CURRENT REPORT view ·
8-K 2025-09-22 CURRENT REPORT view ·
8-K 2025-09-05 CURRENT REPORT view ·
8-K 2025-09-04 CURRENT REPORT view ·
10-Q 2025-08-22 QUARTERLY REPORT view ·
S-1 2025-07-21 REGISTRATION STATEMENT view ·
8-K 2025-07-18 CURRENT REPORT view ·
8-K 2025-07-14 CURRENT REPORT view ·
8-K 2025-07-08 CURRENT REPORT view ·
8-K 2025-06-30 CURRENT REPORT view ·
8-K 2025-06-17 CURRENT REPORT view ·
8-K 2025-06-13 CURRENT REPORT view ·
8-K 2025-06-11 CURRENT REPORT view ·
8-K 2025-06-06 CURRENT REPORT view ·
4 2025-06-02 Insider transaction (Form 4) view ·
4 2025-06-02 Insider transaction (Form 4) view ·
4 2025-06-02 Insider transaction (Form 4) view ·
4 2025-06-02 Insider transaction (Form 4) view ·
4 2025-06-02 Insider transaction (Form 4) view ·
4 2025-06-02 Insider transaction (Form 4) view ·
4 2025-06-02 Insider transaction (Form 4) view ·
4 2025-06-02 Insider transaction (Form 4) view ·
8-K 2025-06-02 CURRENT REPORT view ·
8-K 2025-05-29 CURRENT REPORT view ·
10-Q 2025-05-15 QUARTERLY REPORT view ·
8-K 2025-05-08 CURRENT REPORT view ·
DEF 14A 2025-05-07 PROXY STATEMENT view ·
8-K 2025-04-25 CURRENT REPORT view ·
8-K 2025-04-22 CURRENT REPORT view ·
10-K 2025-04-15 ANNUAL REPORT view ·
4 2025-04-04 Insider transaction (Form 4) view ·
4 2025-03-06 Insider transaction (Form 4) view ·

About CERO

CERo Therapeutics Holdings, Inc., an immunotherapy company, engages in the development of engineered T cell therapeutics for the treatment of cancer. The company's lead development candidate is CER-1236, an autologous T cell therapy candidate for the treatment of hematologic malignancies and solid tumors. The company was incorporated in 2021 and is based in South San Francisco, California.

Options picks · CERO

ITM + OTM ideas from the latest scan

Loading…

Congress trades · CERO

STOCK Act disclosures

Loading…

SEC filings & insiders · CERO

EDGAR · live

Loading…

Holders · CERO

Institutions & insider activity

Loading…